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:   pathological complete response
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:   progesterone receptor
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:   quantitative polymerase chain reaction

1. INTRODUCTION {#cas13426-sec-0001}
===============

*BRCA1* and *BRCA2* genes play important roles in DNA repair, cell cycle checkpoint control, transcriptional regulation, and ubiquitination.[1](#cas13426-bib-0001){ref-type="ref"}, [2](#cas13426-bib-0002){ref-type="ref"}, [3](#cas13426-bib-0003){ref-type="ref"} Thus, deficiencies in these genes can impact the response of cancer cells to chemotherapy drugs. Several studies have demonstrated that BRCA1 or BRCA2 germline mutation carriers were more sensitive than non‐carriers to chemotherapy drugs.[4](#cas13426-bib-0004){ref-type="ref"}, [5](#cas13426-bib-0005){ref-type="ref"}, [6](#cas13426-bib-0006){ref-type="ref"}, [7](#cas13426-bib-0007){ref-type="ref"}, [8](#cas13426-bib-0008){ref-type="ref"}, [9](#cas13426-bib-0009){ref-type="ref"} However, BRCA1/2 germline mutations are rarely observed in sporadic breast cancer, comprising only approximately 2% of breast cancers overall[10](#cas13426-bib-0010){ref-type="ref"}, [11](#cas13426-bib-0011){ref-type="ref"} and approximately 1.1% of breast cancer cases in China.[12](#cas13426-bib-0012){ref-type="ref"}

In addition to BRCA1/2 germline mutations, other BRCA defects, including methylation of the BRCA1 promoter, low expression, and copy number deletions in some sporadic cancers share similar phenotypic characteristics with tumors that carry BRCA1/2 mutations.[13](#cas13426-bib-0013){ref-type="ref"} Decreased BRCA1 mRNA expression in breast cancer cell lines increased sensitivity to etoposide and cisplatin,[14](#cas13426-bib-0014){ref-type="ref"}, [15](#cas13426-bib-0015){ref-type="ref"} whereas overexpression of BRCA1 in murine ovarian cancer cells increased resistance to cisplatin, etoposide, and doxorubicin.[16](#cas13426-bib-0016){ref-type="ref"}, [17](#cas13426-bib-0017){ref-type="ref"} Consistent with these in vitro findings, we previously demonstrated that methylation of the BRCA1 promoter is significantly associated with sensitivity to adjuvant chemotherapy in triple‐negative breast cancer patients and with good outcome.[18](#cas13426-bib-0018){ref-type="ref"} However, several studies also showed that inhibition of BRCA1 expression resulted in resistance to paclitaxel and vincristine.[14](#cas13426-bib-0014){ref-type="ref"}, [19](#cas13426-bib-0019){ref-type="ref"} Moreover, relatively few studies to date have reported the relationship of BRCA2 mRNA expression and response to chemotherapy in breast cancers. Thus, the role of BRCA1 and BRCA2 as predictors of differential response to neoadjuvant chemotherapy in breast cancer has not been well established. In particular, few studies have excluded the effect of BRCA1/2 germline mutations to determine whether BRCA1 or BRCA2 mRNA expression levels contribute to response to chemotherapy agents.

To address these problems, we measured mRNA expression levels of BRCA1 and BRCA2 in a cohort of 674 Chinese breast cancer patients without BRCA1/2 germline mutations who received neoadjuvant chemotherapy. We also evaluated the effect of BRCA1 and BRCA2 mRNA expression levels on the prediction of various neoadjuvant chemotherapy regimens.

2. MATERIALS AND METHODS {#cas13426-sec-0002}
========================

2.1. Patients {#cas13426-sec-0003}
-------------

This study included 774 operable primary breast cancer patients (stage I‐III) who received neoadjuvant chemotherapy at the Breast Center, Peking University Cancer Hospital from May 2004 to January 2011. Breast cancer was diagnosed by a core‐needle biopsy using a 14‐gauge needle at the Breast Center. Fresh core‐needle breast tumor samples were available for all patients. Of these 774 patients, 73 patients were excluded because tumor tissue was unavailable or insufficient for BRCA1 and BRCA2 assessment, poor quality of the RNA samples, or bad repeat results of real‐time quantitative PCR. Of these remaining 701 patients, 27 patients were excluded because they carried BRCA1 or BRCA2 germline mutations. Thus, a total 674 breast cancer patients who were assessed and confirmed as negative for BRCA1/2 germline mutations were analyzed in this study.

Patient age at diagnosis ranged from 25 to 73 years, with a median of 49 years. Tumors were graded according to the modified Bloom‐Richardson system. Tumor stage was classified according to TNM classification of the Union International Cancer Control. Tumor size was defined as the maximum tumor diameter measured by a mammogram and/or ultrasound at the time of diagnosis. Treatments were obtained from review of medical records. This study was conducted in accordance with the ethics principles of the Declaration of Helsinki and approved by the Research and Ethics Committee of Peking University Cancer Hospital. All patients provided written informed consent.

2.2. Neoadjuvant chemotherapy regimens {#cas13426-sec-0004}
--------------------------------------

Among the total 674 BRCA1/2 mutation‐negative patients, 94% received four to eight cycles of neoadjuvant chemotherapy. Treatments were categorized into three subgroups.

A total of 531 patients received an anthracycline‐based regimen. Of these, 236 patients received anthracycline regimens; the common regimens were CTF (5‐fluorouracil, pirarubicin, and cyclophosphamide) or FEC (5‐fluorouracil, epirubicin, and cyclophosphamide) regimens, which were described previously;[20](#cas13426-bib-0020){ref-type="ref"} 118 patients received two cycles of anthracycline regimens followed by four cycles of paclitaxel alone (80 mg/m^2^ i.v. once a week for 12 weeks) or docetaxel plus cyclophosphamide (docetaxel 75 mg/m^2^ i.v. on day 1, cyclophosphamide 600 mg/m^2^ i.v. on day 1, every 3 weeks); and 177 patients received two cycles of anthracycline regimens followed by paclitaxel plus carboplatin (paclitaxel 175 mg/m^2^ i.v. on day 1, or paclitaxel 60 mg/m^2^ i.v. on day 1, day 8, and day 15, and carboplatin AUC6, i.v. on day 1, every 3 weeks).A total of 129 patients received a taxane‐based regimen without anthracyclines. Of these, 94 patients received four cycles of paclitaxel alone; 20 patients received paclitaxel plus carboplatin. The remaining 15 patients received docetaxel plus cyclophosphamide.The remaining 14 patients received other regimens.

After completion of neoadjuvant chemotherapy, patients were treated with mastectomy (n = 398) or breast‐conserving surgery (n = 276) depending on tumor size, presence of multiple lesions or patient preference. pCR was defined as no invasive breast cancer cells in the breast after completion of neoadjuvant chemotherapy.[21](#cas13426-bib-0021){ref-type="ref"}

2.3. Real‐time quantitative PCR {#cas13426-sec-0005}
-------------------------------

Breast tumor RNA was extracted from all core‐needle biopsy samples obtained before the start of neoadjuvant chemotherapy using Trizol reagent (Life Technologies Inc., Gaithersburg, MD, USA) according to the manufacturer\'s instructions. RNA (500 ng) was transcribed to cDNA in a total 20 μL RT reaction solution containing 4.0 μL 5 × first strand buffer, 2.0 μM DTT, 20 U RNase inhibitor, 1 mM dNTP, 1 μM random primer and 200 U superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). Real‐time quantitative PCR reactions of the *BRCA1* and *BRCA2* genes were carried out using the TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in the Applied Biosystems StepOne‐plus Real‐time PCR System, following the manufacturer\'s instructions. We used commercially available primers and probes for PCR analyses (TaqMan Gene Expression Assays, Assay ID: Hs01556193_m1 for BRCA1, Hs00609073_m1 for BRCA2, and Hs99999903_m1 for β‐actin as an endogenous control; Applied Biosystems). PCR conditions were as follows: 95°C for 10 minutes, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Each sample was assayed in triplicate with RNase‐free water as negative control.

Relative gene expression quantifications were calculated according to the comparative Ct method using β‐actin as an endogenous control and normal peripheral blood mononuclear cell RNA control as calibrators in each plate. Final results were determined by the formula 2^−ΔΔCt^ [22](#cas13426-bib-0022){ref-type="ref"} and were analyzed with DataAssist™ software. Results obtained were the mean of three independent experiments.

2.4. BRCA1 and BRCA2 germline mutation analysis by sequencing {#cas13426-sec-0006}
-------------------------------------------------------------

Genomic DNA was isolated from peripheral mononuclear blood cells using the phenol‐chloroform assay. *BRCA1* and *BRCA2* genes were screened by PCR sequencing assay as described elsewhere.[23](#cas13426-bib-0023){ref-type="ref"} We screened the entire coding regions and exon‐intron boundaries of BRCA1 and BRCA2 for all 701 breast cancer patients. All fragments were sequenced using the BigDye Terminator Cycle Sequencing Kit and ABI 3730 automated sequencer (Applied Biosystems). Each mutation was confirmed in duplicate. Only the mutations that lead to a truncated protein or that have been previously reported as disease‐associated (according to Breast Cancer Information Core database) were considered to be deleterious.

2.5. ER, PR, and HER2 status {#cas13426-sec-0007}
----------------------------

ER, PR, and HER2 status were determined by immunostaining in the core‐needle biopsy breast cancer tissue obtained before the start of neoadjuvant chemotherapy. ER or PR immunostaining was considered positive when ≥1% of tumor cells showed positive nuclear staining. HER2 positivity was defined as a score of 3 + (immunohistochemistry) or *HER2* gene amplification (FISH) in core‐biopsy breast cancer tissue.[20](#cas13426-bib-0020){ref-type="ref"}

2.6. Statistical analysis {#cas13426-sec-0008}
-------------------------

Median values and ranges were calculated for mRNA expression. To provide an easily interpretable evaluation of the effect of BRCA1 and BRCA2 mRNA expression, gene expression values were divided into tertiles. Associations between BRCA1 or BRCA2 mRNA levels, clinicopathological characteristics, and pathological response to neoadjuvant chemotherapy were determined by Pearson\'s chi‐squared test. A logistic regression model was applied to determine whether a factor was an independent predictor of pCR in multivariate analysis. DRFS was defined as the time from the date of diagnosis to first distant recurrence (not including second primary malignancies) or death from breast cancer without a recorded relapse. Survival curves were derived from Kaplan‐Meier estimates and compared using log‐rank tests. All statistical tests were two‐sided, and *P*‐values \<.05 were considered statistically significant. Statistical analyses were carried out using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).

3. RESULTS {#cas13426-sec-0009}
==========

3.1. Patient characteristics and BRCA1 and BRCA2 mRNA expression levels {#cas13426-sec-0010}
-----------------------------------------------------------------------

We studied 674 patients who were previously tested and found to be negative for BRCA1/2 germline mutations.[24](#cas13426-bib-0024){ref-type="ref"}, [25](#cas13426-bib-0025){ref-type="ref"} We carried out quantitative real‐time PCR of BRCA1 and BRCA2 mRNA expressions in the 674 total samples negative for BRCA1/2 germline mutations, using the reference gene of β‐actin for normalization. Relative median mRNA expression levels of BRCA1 and BRCA2 were 1.71 (range 0.03‐34.72) and 1.33 (range 0.03‐43.87), respectively. Patients were subdivided into three groups based on low (0.03‐1.08; mean, 0.57), intermediate (1.10‐2.83; mean, 1.82), and high (2.85‐34.7; mean, 6.73) levels of BRCA1 mRNA relative expression. Patients were also divided into three subgroups based on BRCA2 mRNA relative expression: low (0.03‐0.88; mean, 0.52), intermediate (0.91‐1.89; mean, 1.33), and high (1.92‐68.29; mean, 5.17) levels.

Table [1](#cas13426-tbl-0001){ref-type="table-wrap"} shows the clinicopathological characteristics for all patients (n = 674). Patients with low BRCA1 mRNA level were more likely to have ER‐negative (*P* = .002), PR‐negative (*P* = .006), and HER2‐positive expression (*P* = .025), whereas patients with low BRCA2 mRNA level were more likely to be ER‐positive (*P* = .032), PR‐positive (*P* = .01), HER2‐negative (*P* = .011), and lymph node positive (*P* = .027). Patients with low BRCA1 mRNA expression level were also more likely to be triple‐negative (*P* = .014). Neither BRCA1 nor BRCA2 mRNA expression was significantly associated with age at diagnosis or tumor size (Table [1](#cas13426-tbl-0001){ref-type="table-wrap"}).

###### 

Association of patient and tumor characteristics with BRCA1 or BRCA2 mRNA expression status

  Characteristic         N     BRCA1        *P*          BRCA2        *P*                                           
  ---------------------- ----- ------------ ------------ ------------ ------ ------------ ------------ ------------ ------
  Age, years             674   225          225          224          .89    224          225          225          .23
  ≤50                    363   119 (52.9)   124 (55.1)   120 (53.6)          128 (57.1)   124 (55.1)   111 (49.3)   
  \>50                   311   106 (47.1)   101 (44.9)   104 (46.4)          96 (42.9)    101 (44.9)   114 (50.7)   
  Tumor size,                                                         .55                                           .16
  ≤2 cm                  224   81 (36.0)    71 (31.6)    72 (32.1)           78 (34.8)    64 (28.4)    82 (36.4)    
  \>2 cm                 450   144 (64.0)   154 (68.4)   152 (67.9)          146 (65.2)   161 (71.6)   143 (63.6)   
  Lymph node status                                                   .69                                           .027
  Negative               355   123 (54.7)   119 (53.1)   113 (50.7)          102 (45.7)   130 (58.0)   123 (54.7)   
  Positive               317   102 (45.3)   105 (46.9)   110 (49.3)          121 (54.3)   94 (42.0)    102 (45.3)   
  Unknown                2                                                                                          
  Tumor grade                                                         .17                                           .06
  I                      46    17 (7.8)     12 (5.5)     17 (7.8)            17 (7.9)     14 (6.4)     15 (6.8)     
  II                     501   155 (71.1)   176 (80.0)   170 (78.0)          175 (81.0)   167 (76.6)   159 (71.6)   
  III                    109   46 (21.1)    32 (14.5)    31 (14.2)           24 (11.1)    37 (17.0)    48 (21.6)    
  Unknown                18                                                                                         
  ER status                                                           .002                                          .032
  Negative               230   97 (43.1)    64 (28.7)    69 (30.8)           65 (29.0)    74 (33.0)    91 (40.6)    
  Positive               442   128 (56.9)   159 (71.3)   155 (69.2)          159 (71.0)   150 (67.0)   133 (59.4)   
  Unknown                2                                                                                          
  PR status                                                           .006                                          .01
  Negative               299   119 (53.6)   88 (39.6)    92 (41.8)           82 (37.4)    102 (45.7)   115 (51.8)   
  Positive               365   103 (46.4)   134 (60.4)   128 (58.2)          137 (62.6)   121 (54.3)   107 (48.2)   
  Unknown                10                                                                                         
  HER2 status                                                         .025                                          .011
  Negative               465   149 (66.5)   146 (64.9)   170 (75.9)          171 (76.3)   151 (67.4)   143 (63.6)   
  Positive               208   75 (33.5)    79 (35.1)    54 (24.1)           53 (23.7)    73 (32.6)    82 (36.4)    
  Unknown                1                                                                                          
  Triple‐negative                                                     .014                                          0.17
  Yes                    123   53 (23.6)    29 (12.9)    41 (18.3)           36 (16.1)    37 (16.4)    50 (22.2)    
  No                     551   172 (76.4)   196 (87.1)   183 (81.7)          188 (83.9)   188 (83.6)   175 (77.8)   
  Surgery type                                                        .14                                           .19
  BCS                    276   91 (40.4)    103 (45.8)   82 (36.6)           91 (40.6)    83 (36.9)    102 (45.3)   
  Mastectomy             398   134 (59.6)   122 (54.2)   142 (63.4)          133 (59.4)   142 (63.1)   123 (54.7)   
  Chemotherapy                                                        .92                                           .35
  Anthracycline‐ based   531   175 (77.8)   178 (79.1)   178 (79.5)          177 (79.0)   171 (76.0)   183 (81.3)   
  Taxane                 129   46 (20.4)    41 (18.2)    42 (18.8)           45 (20.1)    47 (20.9)    37 (16.4)    
  Others                 14    4 (1.8)      6 (2.7)      4 (1.8)             2 (0.9)      7 (3.1)      5 (2.2)      

BCS, breast‐conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor‐2; PR, progesterone receptor.

John Wiley & Sons, Ltd

3.2. Response to neoadjuvant chemotherapy {#cas13426-sec-0011}
-----------------------------------------

Among the 674 BRCA1/2 germline mutation negative patients, 129 patients (19.1%, 129/674) achieved pCR. Patients with low BRCA1 mRNA level had a higher pCR rate than those with intermediate or high BRCA1 mRNA level (23.6% vs 18.7% or 15.2%, respectively; *P* = .077), but the difference did not reach statistical significance. Low, intermediate or high BRCA2 mRNA expression level was not significantly associated with pCR rate (18.7%, 18.2% or 20.4%, respectively; *P* = .82). Additional factors associated with pCR included tumor size (*P* = .003), lymph node status (*P* \< .001), tumor grade (*P* \< .001), ER status (*P* \< .001), PR status (*P* \< .001), and HER2 status (*P* = .01) (Table [2](#cas13426-tbl-0002){ref-type="table-wrap"}).

###### 

Pathological complete response rates by clinical characteristics and BRCA1 or BRCA2 mRNA expression level

  Characteristic        N     Non‐pCR      pCR         *P*‐value
  --------------------- ----- ------------ ----------- -----------
  Age, years                                           .28
  ≤50                   363   299 (82.4)   64 (17.6)   
  \>50                  311   246 (79.1)   65 (20.9)   
  Tumor size, cm                                       .003
  ≤2                    224   167 (74.6)   57 (25.4)   
  \>2                   450   378 (84.0)   72 (16.0)   
  Lymph node status                                    \<.001
  Negative              355   262 (73.8)   93 (26.2)   
  Positive              317   281 (88.6)   36 (11.4)   
  Unknown               2                              
  Tumor grade                                          \<.001
  I                     46    41 (89.1)    5 (10.9)    
  II                    501   416 (83.0)   85 (17.0)   
  III                   109   70 (64.2)    39 (35.8)   
  Unknown               18                             
  ER status                                            \<.001
  Negative              230   149 (64.8)   81 (35.2)   
  Positive              442   394 (89.1)   48 (10.9)   
  PR status                                            \<.001
  Negative              299   210 (39.1)   89 (70.1)   
  Positive              365   327 (60.9)   38 (29.9)   
  HER2 status                                          .01
  Negative              465   388 (83.4)   77 (16.6)   
  Positive              208   156 (75.0)   52 (25.0)   
  Chemotherapy type                                    .52
  Anthracycline based   531   433 (81.5)   98 (18.5)   
  Taxane                129   100 (77.5)   29 (22.5)   
  Others                14    12 (85.7)    2 (14.3)    
  BRCA1                                                .077
  Low                   225   172 (76.4)   53 (23.6)   
  Intermediate          225   183 (81.3)   42 (18.7)   
  High                  224   190 (84.8)   34 (15.2)   
  BRCA2                                                .82
  Low                   224   182 (81.3)   42 (18.7)   
  Intermediate          225   184 (81.8)   41 (18.2)   
  High                  225   179 (79.6)   46 (20.4)   

BCS, breast‐conserving surgery; ER, estrogen receptor; HER2, human epidermal growth factor receptor‐2; pCR, pathological complete response; PR, progesterone receptor.

John Wiley & Sons, Ltd

Patients were also divided into three treatment subgroups according to treatment regimen. No significant differences in BRCA1 and BRCA2 mRNA expression were found among the anthracycline‐based treatment group, taxane‐treated group, and other regimen groups (*P* = .92 and *P* = .35, respectively) (Table [1](#cas13426-tbl-0001){ref-type="table-wrap"}). pCR rates were also not significantly different in the three treatment groups (18.5% vs 22.5% vs 14.3%, *P* = .52) (Table [2](#cas13426-tbl-0002){ref-type="table-wrap"}).

Among the patients who received anthracycline with or without taxane‐based neoadjuvant chemotherapy regimen (n = 531), patients with low BRCA1 mRNA expression had significantly higher pCR rate than intermediate or high BRCA1 mRNA level patients (24.6% vs 16.9% or 14.0%, respectively; *P* = .031) (Table [3](#cas13426-tbl-0003){ref-type="table-wrap"}). In multivariate analysis, low BRCA1 mRNA expression showed a borderline significance (OR = 1.54; 95% CI, 0.93‐2.56; *P* = .094) for correlation with pCR to anthracycline‐based chemotherapy after adjusting for age, tumor size, tumor grade, ER and PR status, and HER2 status (Table [4](#cas13426-tbl-0004){ref-type="table-wrap"}). However, BRCA2 mRNA expression level was not associated with pCR rate in patients with anthracycline‐based neoadjuvant chemotherapy (16.9%, 17.5% and 20.8% in low, intermediate and high BRCA2 mRNA groups, respectively; *P* = .60) (Table [3](#cas13426-tbl-0003){ref-type="table-wrap"}).

###### 

pCR rate based on BRCA1 or BRCA2 mRNA expression status according to neoadjuvant chemotherapy regimens

  Regimens                        No. patients   Non‐pCR   pCR     *P*‐value          
  ------------------------------- -------------- --------- ------- ----------- ------ ------
  Anthracycline‐based (n = 531)                                                       
  BRCA1                                                                               .031
  Low                             175            132       75.4    43          24.6   
  Intermediate                    178            148       83.1    30          16.9   
  High                            178            153       86.0    25          14.0   
  BRCA2                                                                               .60
  Low                             177            147       83.1    30          16.9   
  Intermediate                    171            141       82.5    30          17.5   
  High                            183            145       79.2    38          20.8   
  Taxane (n = 129)                                                                    
  BRCA1                                                                               .71
  Low                             46             37        80.4    9           19.6   
  Intermediate                    41             30        73.2    11          26.8   
  High                            42             33        78.6    9           21.4   
  BRCA2                                                                               .82
  Low                             45             34        75.6    11          24.4   
  Intermediate                    47             36        76.6    11          23.4   
  High                            37             30        81.1    7           18.9   
  Others (n = 14)                                                                     
  BRCA1                                                                               .57
  Low                             4              3         75.0    1           25.0   
  Intermediate                    6              5         83.3    1           16.7   
  High                            4              4         100.0   0           0      
  BRCA2                                                                               .18
  Low                             2              1         50.0    1           50.0   
  Intermediate                    7              7         100.0   0           0      
  High                            5              4         80.0    1           20.0   

pCR, pathological complete response.

John Wiley & Sons, Ltd

###### 

Multivariate analysis of pathological complete response in anthracycline‐based group

  Variable                   Pathological complete response               
  -------------------------- -------------------------------- ----------- --------
  Age                                                                     
  ≤50 y vs \>50 y            1.19                             0.71‐2.01   .50
  ER status                                                               
  Negative vs Positive       3.01                             1.43‐6.33   .004
  PR status                                                               
  Positive vs Negative       1.50                             0.70‐3.21   .30
  HER2 status                                                             
  Negative vs Positive       1.43                             0.85‐2.42   .18
  Tumor size                                                              
  ≤2 cm vs \>2 cm            2.28                             1.36‐3.82   .002
  Tumor grade                                                             
  III vs I/II                2.41                             1.32‐4.40   .004
  Lymph node status                                                       
  Negative vs Positive       4.93                             2.47‐9.84   \<.001
  BRCA1                                                                   
  Low vs Intermediate/High   1.54                             0.93‐2.56   .094

CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor‐2; OR, odds ratio; PR, progesterone receptor.

John Wiley & Sons, Ltd

Among the patients who received taxane‐based neoadjuvant chemotherapy (n = 129), pCR rate was not significantly associated with BRCA1 mRNA (19.6%, 26.8% and 21.4% in low, intermediate and high BRCA1 groups, respectively; *P* = .71) or BRCA2 mRNA level (24.4%, 23.4% and 18.9%; *P* = .82) (Table [3](#cas13426-tbl-0003){ref-type="table-wrap"}).

3.3. Survival estimates {#cas13426-sec-0012}
-----------------------

Follow‐up data were available for all patients; median follow‐up time was 66 months (range 5‐113 months). A total of 116 (17.2%) patients experienced a distant recurrence or died of breast cancer during the follow‐up period. The estimated 5‐year DRFS for the entire study population was 83.3% (95% CI, 80.4%‐86.2%). The estimated 5‐year DRFS rates for anthracycline‐based and taxane‐based treated groups were 82.3% (78.9%‐85.6%) and 87.4% (81.3%‐93.5%), respectively. The sample size of patients who received other regimens was relatively small, so the survival curve was not analyzed in this subgroup. Patients who achieved a pCR had a significantly better 5‐year DRFS rate than patients who did not, in the entire patient (92.8% vs 81.1%, *P* = .001) (Figure [1](#cas13426-fig-0001){ref-type="fig"}A) or in anthracycline‐based groups (91.7% vs 80.2%, *P* = .006) (Figure [1](#cas13426-fig-0001){ref-type="fig"}B). Among taxane‐based treated groups, patients who achieved pCR also had a better 5‐year DRFS rate than patients who did not, but the difference did not reach statistical significance (96.4% vs 86.6%, *P* = .12) (Figure [1](#cas13426-fig-0001){ref-type="fig"}C).

![Kaplan‐Meier estimates of distant recurrence‐free survival by pathological complete response (pCR) status in (A) the entire 674 breast cancer patients who received neoadjuvant chemotherapy, (B) the 531 patients who received anthracycline‐based neoadjuvant chemotherapy, and (C) the 129 patients who received taxane‐based neoadjuvant chemotherapy](CAS-109-166-g001){#cas13426-fig-0001}

Because BRCA1 mRNA level was associated with pCR in the 531 patients who received anthracycline‐based neoadjuvant chemotherapy, we next analyzed the association between pCR and DRFS according to the BRCA1 mRNA level in this subgroup. There was no significant difference in 5‐year DRFS between BRCA1 low and intermediate or high mRNA level (84.7% vs 81.5%, *P* = .97) (Figure [2](#cas13426-fig-0002){ref-type="fig"}A). Patients who achieved pCR had better 5‐year DRFS compared with those who did not achieve pCR, in both BRCA1 low and intermediate or high mRNA groups (*P* = .044, Figure [2](#cas13426-fig-0002){ref-type="fig"}B).

![Kaplan‐Meier estimates of distant recurrence‐free survival (DRFS) by BRCA1 mRNA expression level and pathological complete response (pCR) status in 531 breast cancer patients who received anthracycline‐based neoadjuvant chemotherapy. (A) DRFS by BRCA1 mRNA expression level. (B) DRFS by BRCA1 mRNA expression level and pCR status](CAS-109-166-g002){#cas13426-fig-0002}

4. DISCUSSION {#cas13426-sec-0013}
=============

In the present study, we investigated the association between BRCA1 and BRCA2 mRNA levels and response to neoadjuvant chemotherapy in 674 Chinese breast cancer patients without BRCA1/2 germline mutations. We found that patients with low expression of BRCA1 mRNA were more likely to respond to anthracycline‐based neoadjuvant chemotherapy than patients with intermediate or high BRCA1 mRNA levels.

The total 674 breast cancer patients included in this study received different chemotherapy regimens. Among the 531 patients treated with an anthracyline‐based regimen, patients with low BRCA1 mRNA level had a significantly higher pCR rate than patients with intermediate or high BRCA1 mRNA level. However, among the 129 patients that received a taxane‐based regimen, pCR rate was not different in BRCA1 low, intermediate, and high mRNA level subgroups (*P* = .71). BRCA2 mRNA level was not associated with pCR rate in either the anthracyline‐based treated subgroup (*P* = .60) or the taxane‐based regimen subgroup (*P* = .82).

Previous studies reported the association between BRCA1 and BRCA2 expression and response to chemotherapy; however, the results shown were less consistent.[26](#cas13426-bib-0026){ref-type="ref"}, [27](#cas13426-bib-0027){ref-type="ref"}, [28](#cas13426-bib-0028){ref-type="ref"} Some clinical data suggested that tumors with low BRCA1 or BRCA2 mRNA expression responded better to DNA‐damaging chemotherapy,[27](#cas13426-bib-0027){ref-type="ref"}, [28](#cas13426-bib-0028){ref-type="ref"}, [29](#cas13426-bib-0029){ref-type="ref"} whereas some showed no relationship between BRCA1 or BRCA2 expression and chemotherapy sensitivity.[28](#cas13426-bib-0028){ref-type="ref"}, [30](#cas13426-bib-0030){ref-type="ref"} However, the sample size of previous studies was relatively small. Moreover, the previous studies did not take the BRCA1/2 germline mutations into consideration when investigating the relationship between mRNA expression level of BRCA1/2 and response to neoadjuvant chemotherapy, as BRCA1 germline mutations may affect the response to some chemotherapy drugs.[31](#cas13426-bib-0031){ref-type="ref"} One advantage of the current study was that the germline mutations of *BRCA1* and *BRCA2* genes in this cohort had been analyzed through sequencing assay, and BRCA1/2 gene germline mutations status was clearly shown in our previous reports.[24](#cas13426-bib-0024){ref-type="ref"}, [25](#cas13426-bib-0025){ref-type="ref"} To the best of our knowledge, this is the first study to report that BRCA1 and BRCA2 mRNA expression level was associated with response to neoadjuvant chemotherapy in a relatively large sample size, excluding the effects of *BRCA1* and *BRCA2* gene mutations.

*BRCA1* gene plays an important role in DNA damage repair, regulation of gene expression and cell cycle control. Tumors with low expression of BRCA1 mRNA are certainly different from typical tumors with BRCA1 germline mutation. However, there are some similarities between the morphology and molecular biology of breast cancer with low expression BRCA1 and BRCA1 mutated breast cancer that have led to the concept of "BRCAness". Both BRCA1 mutated breast cancers and reduced BRCA1 expression tend to be higher grade, hormone receptor‐negative, and HER2‐negative, or "triple negative" and frequently express a basal phenotype.[13](#cas13426-bib-0013){ref-type="ref"}, [32](#cas13426-bib-0032){ref-type="ref"}, [33](#cas13426-bib-0033){ref-type="ref"}, [34](#cas13426-bib-0034){ref-type="ref"} In vitro and in vivo studies have shown that cells deficient for BRCA1 could be more sensitive to chemotherapy agents that produce DNA damage through double‐strand DNA breaks, such as anthracyclines and etoposide.[14](#cas13426-bib-0014){ref-type="ref"}, [15](#cas13426-bib-0015){ref-type="ref"}, [17](#cas13426-bib-0017){ref-type="ref"}, [19](#cas13426-bib-0019){ref-type="ref"} These preclinical observations are consistent with our results. Our findings indicate that patients with low BRCA1 mRNA level were more likely to respond to anthracycline‐based neoadjuvant chemotherapy and gained more benefit from anthracycline‐based therapy compared with patients with intermediate or high BRCA1 mRNA level, but this was not evident for BRCA2 mRNA expression. This may be because the relative roles of BRCA1 and BRCA2 in DNA repair of DNA double‐strand breaks were not exactly the same. BRCA1 is a critical organizing molecule that has been linked to a range of cellular processes beyond DNA repair, such as transcriptional regulation and chromatin remodeling. Tumor cells with deficient BRCA1 may respond better to DNA‐damaging chemotherapy. BRCA2 function in homologous recombination is primarily through regulation of RAD51 activity.[1](#cas13426-bib-0001){ref-type="ref"}, [17](#cas13426-bib-0017){ref-type="ref"}, [35](#cas13426-bib-0035){ref-type="ref"}

The present study had several limitations. Neoadjuvant chemotherapy regimens were not assigned randomly, and a small number of patients received taxane‐based neoadjuvant chemotherapy.

In summary, our study suggests that in the absence of BRCA1/2 germline mutations, breast cancer patients with low BRCA1 mRNA expression have a higher pCR rate to anthracycline‐based neoadjuvant chemotherapy, but not to taxane regimens. Although BRCA2 plays an important role in DNA repair, BRCA2 mRNA expression may not predict response to anthracycline‐based or taxane neoadjuvant chemotherapy. Nevertheless, future studies are warranted to confirm our current findings.
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